Perseus Proteomics, Inc. (JP:4882) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Perseus Proteomics Inc. has announced the extension of its phase I/II clinical trial for its drug PPMX-T003, targeting the rare aggressive NK-cell leukemia, until March 2026 due to challenges in subject registration. The company is analyzing the potential impact of this extension on its financial results for the current and following fiscal years.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.